pneumatic compression device for cancer patients

#Pneumatic compression device for cancer patients trial
#Pneumatic compression device for cancer patients plus

Lymphedema is often linked to psychological distress and decreased quality of life. Lymphedema involving internal structures such as the pharynx or larynx may result in airway compromise and/or dysphagia. External lymphedema of the face and neck is associated with decreased range of motion (ROM), abnormal posture, and musculoskeletal discomfort. Lymphedema manifestations vary depending on the involved site. In one prospective trial, over 90% of HNC patients developed lymphedema at some time during the course of their treatment and early recovery. Head and neck cancer (HNC) and its therapy are associated with damage to lymphatic structures resulting in secondary lymphedema. In addition, preliminary data supports efficacy.

#Pneumatic compression device for cancer patients trial

This trial supports the safety and feasibility of the APCD for the treatment of secondary lymphedema in head and neck cancer patients. APCD use was associated with significant improvement in perceived ability to control lymphedema ( p = 0.003) and visible external swelling (front view p < 0.001, right view p = 0.004, left p = 0.005), as well as less reported pain. Most patients used the APCD once per day, instead of the prescribed twice per day, citing time related factors as barriers to use. No device-related Serious Adverse Events were reported. In total, forty-three patients completed the study. Resultsįorty-nine patients were enrolled (wait-list n = 25 intervention n = 24). Assessments were conducted at baseline and weeks 4 and 8. Safety (CTCAE V4.0) and feasibility were primary endpoints secondary endpoints included efficacy measure by objective examination and patient reported outcomes (symptoms, quality of life, function), adherence barriers, and satisfaction.

#Pneumatic compression device for cancer patients plus

Participants were randomized to wait-list lymphedema self-management (standard of care) or lymphedema self-management plus the use of the APCD bid. Material and methodsĮligible patients had completed treatment for HNC, were disease free, and had lymphedema at enrollment. A randomized, wait-list controlled trial was undertaken to evaluate an APCD in post-treatment HNC patients with lymphedema. Advanced pneumatic compression devices (APCD) may address these issues. Cost and availability of trained therapists are known barriers to therapy. Standard treatment includes professionally administered complete decongestive therapy (CDT). Lymphedema associated with head and neck cancer (HNC) therapy causes adverse clinical outcomes.